The anti-peptic ulcer drugs industry is witnessing significant expansion due to the rising prevalence of gastrointestinal disorders across developed and emerging economies. Increasing cases of gastric ulcers, duodenal ulcers, gastritis, and gastroesophageal reflux disease (GERD) are encouraging pharmaceutical companies to strengthen their therapeutic portfolios and invest in advanced treatment...